Bill targets drug execs
This article was originally published in The Tan Sheet
Executive SummaryPharmaceutical executives who knowingly withhold from the public information on serious adverse events associated with their products would be subject to criminal penalties under the "Pharmaceutical Research & Manufacturers Accountability Act," or PhRma Act (HR 870), introduced in the House Feb. 16 by Reps. Pete Stark (D-Calif.) and Marion Berry (D-Ark.). Violators would be subject to 20-year minimum prison sentences and/or fines of up to $2 mil. CEOs would be required to issue annual reports on adverse drug experiences for their firms' products...
You may also be interested in...
Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.
FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.
Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.